Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients.

Chan JK, Hernandez Martínez de Lapiscina E, Taylor C, Nguyen AL, Alba-Arbalat S, Devonshire V, Sayao AL, Carruthers R, Costello F, Traboulsee A.

J Neuroophthalmol. 2020 Mar;40(1):37-43. doi: 10.1097/WNO.0000000000000802.

PMID:
32045393
2.

Myelin water imaging data analysis in less than one minute.

Liu H, Xiang QS, Tam R, Dvorak AV, MacKay AL, Kolind SH, Traboulsee A, Vavasour IM, Li DKB, Kramer JK, Laule C.

Neuroimage. 2020 Jan 21;210:116551. doi: 10.1016/j.neuroimage.2020.116551. [Epub ahead of print]

3.

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.

Comi G, Alroughani R, Boster AL, Bass AD, Berkovich R, Fernández Ó, Kim HJ, Limmroth V, Lycke J, Macdonell RA, Sharrack B, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Jacobs A, Daizadeh N, Rodriguez CE, Traboulsee A; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators.

Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610. [Epub ahead of print]

PMID:
31762387
4.

Myelin Damage in Normal Appearing White Matter Contributes to Impaired Cognitive Processing Speed in Multiple Sclerosis.

Abel S, Vavasour I, Lee LE, Johnson P, Ackermans N, Chan J, Dvorak A, Schabas A, Wiggermann V, Tam R, Kuan AJ, Morrow SA, Wilken J, Laule C, Rauscher A, Bhan V, Sayao AL, Devonshire V, Li DK, Carruthers R, Traboulsee A, Kolind SH.

J Neuroimaging. 2019 Nov 24. doi: 10.1111/jon.12679. [Epub ahead of print]

PMID:
31762132
5.

Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression.

Law MT, Traboulsee AL, Li DK, Carruthers RL, Freedman MS, Kolind SH, Tam R.

Mult Scler J Exp Transl Clin. 2019 Nov 6;5(4):2055217319885983. doi: 10.1177/2055217319885983. eCollection 2019 Oct-Dec.

6.

Association of Unemployment and Informal Care with Stigma in Multiple Sclerosis: Evidence from the Survey on Living with Neurological Conditions in Canada.

Hategeka C, Traboulsee AL, McMullen K, Lynd LD.

Int J MS Care. 2019 Sep-Oct;21(5):214-225. doi: 10.7224/1537-2073.2017-108.

7.

Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a.

MacMillan EL, Schubert JJ, Vavasour IM, Tam R, Rauscher A, Taylor C, White R, Garren H, Clayton D, Levesque V, Li DK, Kolind SH, Traboulsee AL.

Mult Scler J Exp Transl Clin. 2019 Oct 15;5(4):2055217319879952. doi: 10.1177/2055217319879952. eCollection 2019 Oct-Dec.

8.

Analysis of galanin receptor GALR2 in multiple sclerosis.

Encarnacion M, Bernales CQ, Traboulsee AL, Sadovnick AD, Vilariño-Güell C.

Pharmacogenomics J. 2019 Dec;19(6):499-500. doi: 10.1038/s41397-019-0100-6. Epub 2019 Oct 14. No abstract available.

PMID:
31611593
9.

Cannabis-based product use in a multiple sclerosis cohort.

Schabas AJ, Vukojevic V, Taylor C, Thu Z, Badyal A, Chan JK, Devonshire V, Traboulsee A, Sayao AL, Carruthers R.

Mult Scler J Exp Transl Clin. 2019 Sep 25;5(3):2055217319869360. doi: 10.1177/2055217319869360. eCollection 2019 Jul-Sep.

10.

FLAIR2 improves LesionTOADS automatic segmentation of multiple sclerosis lesions in non-homogenized, multi-center, 2D clinical magnetic resonance images.

Le M, Tang LYW, Hernández-Torres E, Jarrett M, Brosch T, Metz L, Li DKB, Traboulsee A, Tam RC, Rauscher A, Wiggermann V.

Neuroimage Clin. 2019;23:101918. doi: 10.1016/j.nicl.2019.101918. Epub 2019 Jul 5.

11.

Perspectives About Time Frames in Stem Cell Research for Multiple Sclerosis: "Time Is Brain".

Benjaminy S, Lo C, Schepmyer A, Traboulsee A, Illes J.

Int J MS Care. 2019 Jul-Aug;21(4):185-193. doi: 10.7224/1537-2073.2018-102.

12.

Data fusion detects consistent relations between non-lesional white matter myelin, executive function, and clinical characteristics in multiple sclerosis.

Baumeister TR, Lin SJ, Vavasour I, Kolind S, Kosaka B, Li DKB, Traboulsee A, MacKay A, McKeown MJ.

Neuroimage Clin. 2019;24:101926. doi: 10.1016/j.nicl.2019.101926. Epub 2019 Jul 2.

13.

Myelin Water Fraction and Intra/Extracellular Water Geometric Mean T2 Normative Atlases for the Cervical Spinal Cord from 3T MRI.

Liu H, Ljungberg E, Dvorak AV, Lee LE, Yik JT, MacMillan EL, Barlow L, Li DKB, Traboulsee A, Kolind SH, Kramer JLK, Laule C.

J Neuroimaging. 2020 Jan;30(1):50-57. doi: 10.1111/jon.12659. Epub 2019 Aug 13.

PMID:
31407400
14.

Author response: Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial.

Traboulsee A, Machan L.

Neurology. 2019 Aug 13;93(7):320. doi: 10.1212/WNL.0000000000007955. No abstract available.

PMID:
31405940
15.

Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD.

Cook LJ, Rose JW, Alvey JS, Jolley AM, Kuhn R, Marron B, Pederson M, Enriquez R, Yearley J, McKechnie S, Han MH, Tomczak AJ, Levy M, Mealy MA, Coleman J, Bennett JL, Johnson R, Barnes-Garcia M, Traboulsee AL, Carruthers RL, Lee LE, Schubert JJ, McMullen K, Kister I, Rimler Z, Reid A, Sicotte NL, Planchon SM, Cohen JA, Ivancic D, Sedlak JL, Sand IK, Repovic P, Amezcua L, Pruitt A, Amundson E, Chitnis T, Mullin DS, Klawiter EC, Russo AW, Riley CS, Onomichi KB, Levine L, Nelson KE, Nealon NM, Engel C, Kruse-Hoyer M, Marcille M, Tornes L, Rumpf A, Greer A, Kenneally Behne M, Rodriguez RR, Behne DW, Blackway DW, Coords B, Blaschke TF, Sheard J, Smith TJ, Behne JM, Yeaman MR; Guthy-Jackson Charitable Foundation International Clinical Consortium (GJCF–ICC).

Neurol Neuroimmunol Neuroinflamm. 2019 Jun 28;6(5):e583. doi: 10.1212/NXI.0000000000000583. eCollection 2019 Sep.

16.

Myelin Water Atlas: A Template for Myelin Distribution in the Brain.

Liu H, Rubino C, Dvorak AV, Jarrett M, Ljungberg E, Vavasour IM, Lee LE, Kolind SH, MacMillan EL, Traboulsee A, Lang DJ, Rauscher A, Li DKB, MacKay AL, Boyd LA, Kramer JLK, Laule C.

J Neuroimaging. 2019 Nov;29(6):699-706. doi: 10.1111/jon.12657. Epub 2019 Jul 25.

PMID:
31347238
17.

Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients.

Bansback N, Chiu JA, Carruthers R, Metcalfe R, Lapointe E, Schabas A, Lenzen M, Lynd LD, Traboulsee A.

BMC Neurol. 2019 Jul 20;19(1):173. doi: 10.1186/s12883-019-1382-7.

18.

Rapid myelin water imaging for the assessment of cervical spinal cord myelin damage.

Dvorak AV, Ljungberg E, Vavasour IM, Liu H, Johnson P, Rauscher A, Kramer JLK, Tam R, Li DKB, Laule C, Barlow L, Briemberg H, MacKay AL, Traboulsee A, Kozlowski P, Cashman N, Kolind SH.

Neuroimage Clin. 2019;23:101896. doi: 10.1016/j.nicl.2019.101896. Epub 2019 Jun 17.

19.

Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.

Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, Geurts JJG, Paul F, Reich DS, Toosy AT, Traboulsee A, Wattjes MP, Yousry TA, Gass A, Lubetzki C, Weinshenker BG, Rocca MA.

Brain. 2019 Jul 1;142(7):1858-1875. doi: 10.1093/brain/awz144.

20.

Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease.

Vilariño-Güell C, Zimprich A, Martinelli-Boneschi F, Herculano B, Wang Z, Matesanz F, Urcelay E, Vandenbroeck K, Leyva L, Gris D, Massaad C, Quandt JA, Traboulsee AL, Encarnacion M, Bernales CQ, Follett J, Yee IM, Criscuoli MG, Deutschländer A, Reinthaler EM, Zrzavy T, Mascia E, Zauli A, Esposito F, Alcina A, Izquierdo G, Espino-Paisán L, Mena J, Antigüedad A, Urbaneja-Romero P, Ortega-Pinazo J, Song W, Sadovnick AD.

PLoS Genet. 2019 Jun 6;15(6):e1008180. doi: 10.1371/journal.pgen.1008180. eCollection 2019 Jun.

21.

Three-dimensional MRI sequences in MS diagnosis and research.

Hu XY, Rajendran L, Lapointe E, Tam R, Li D, Traboulsee A, Rauscher A.

Mult Scler. 2019 Nov;25(13):1700-1709. doi: 10.1177/1352458519848100. Epub 2019 May 22.

PMID:
31116071
22.

Laboratory Monitoring Practices Among Canadian Multiple Sclerosis Clinicians.

Atwal A, Schabas A, Head J, Taylor C, Traboulsee A, Barclay K, Carruthers R.

Can J Neurol Sci. 2019 Jul;46(4):389-393. doi: 10.1017/cjn.2019.19. Epub 2019 May 21.

PMID:
31111800
23.

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.

Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV.

Front Neurol. 2019 Mar 22;10:253. doi: 10.3389/fneur.2019.00253. eCollection 2019. Review.

24.

Intra- and inter-site reproducibility of human brain single-voxel proton MRS at 3 T.

Graf C, MacMillan EL, Fu E, Harris T, Traboulsee A, Vavasour IM, MacKay AL, Mädler B, Li DKB, Laule C.

NMR Biomed. 2019 Jun;32(6):e4083. doi: 10.1002/nbm.4083. Epub 2019 Mar 19.

PMID:
30889311
25.

Longitudinal advanced MRI case report of white matter radiation necrosis.

Wiggermann V, Lapointe E, Litvin L, Graf C, Hernández-Torres E, McKenzie M, Vavasour IM, Laule C, MacMillan EL, Li DKB, Kolind SH, Rauscher A, Traboulsee AL.

Ann Clin Transl Neurol. 2018 Dec 10;6(2):379-385. doi: 10.1002/acn3.704. eCollection 2019 Feb.

26.

Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.

Mayer L, Kappos L, Racke MK, Rammohan K, Traboulsee A, Hauser SL, Julian L, Köndgen H, Li C, Napieralski J, Zheng H, Wolinsky JS.

Mult Scler Relat Disord. 2019 May;30:236-243. doi: 10.1016/j.msard.2019.01.044. Epub 2019 Jan 28.

PMID:
30844611
27.

Effect of different doses of gadolinium contrast agent on clinical outcomes in MS.

Ackermans N, Taylor C, Tam R, Carruthers R, Kolind S, Kang H, Freedman MS, Li DK, Traboulsee AL.

Mult Scler J Exp Transl Clin. 2019 Feb 16;5(1):2055217318823796. doi: 10.1177/2055217318823796. eCollection 2019 Jan-Mar.

28.

Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS.

Oh J, Ontaneda D, Azevedo C, Klawiter EC, Absinta M, Arnold DL, Bakshi R, Calabresi PA, Crainiceanu C, Dewey B, Freeman L, Gauthier S, Henry R, Inglese M, Kolind S, Li DKB, Mainero C, Menon RS, Nair G, Narayanan S, Nelson F, Pelletier D, Rauscher A, Rooney W, Sati P, Schwartz D, Shinohara RT, Tagge I, Traboulsee A, Wang Y, Yoo Y, Yousry T, Zhang Y, Sicotte NL, Reich DS; North American Imaging in Multiple Sclerosis Cooperative.

Neurology. 2019 Mar 12;92(11):519-533. doi: 10.1212/WNL.0000000000007099. Epub 2019 Feb 20. Review. Erratum in: Neurology. 2019 Jul 2;93(1):46.

PMID:
30787160
29.

Advanced imaging findings in progressive solitary sclerosis: a single lesion or a global disease?

Lee LE, Chan JK, Nevill E, Soares A, Vavasour IM, MacMillan EL, Garren H, Clayton D, Keegan BM, Tam R, Traboulsee AL, Kolind SH, Carruthers RL.

Mult Scler J Exp Transl Clin. 2019 Jan 16;5(1):2055217318824612. doi: 10.1177/2055217318824612. eCollection 2019 Jan-Mar.

30.

Quantitative neuroimaging measures of myelin in the healthy brain and in multiple sclerosis.

O'Muircheartaigh J, Vavasour I, Ljungberg E, Li DKB, Rauscher A, Levesque V, Garren H, Clayton D, Tam R, Traboulsee A, Kolind S.

Hum Brain Mapp. 2019 May;40(7):2104-2116. doi: 10.1002/hbm.24510. Epub 2019 Jan 15.

31.

Case of alemtuzumab-related alopecia areata management in MS.

Chan JK, Traboulsee AL, Sayao AL.

Neurol Neuroimmunol Neuroinflamm. 2018 Oct 19;6(1):e516. doi: 10.1212/NXI.0000000000000516. eCollection 2019 Jan. No abstract available.

32.

Perspectives of Patients with Multiple Sclerosis on Drug Treatment: A Qualitative Study.

Lynd LD, Henrich NJ, Hategeka C, Marra CA, Mittmann N, Evans C, Traboulsee AL.

Int J MS Care. 2018 Nov-Dec;20(6):269-277. doi: 10.7224/1537-2073.2017-109.

33.

Inter-Vendor Reproducibility of Myelin Water Imaging Using a 3D Gradient and Spin Echo Sequence.

Lee LE, Ljungberg E, Shin D, Figley CR, Vavasour IM, Rauscher A, Cohen-Adad J, Li DKB, Traboulsee AL, MacKay AL, Lee J, Kolind SH.

Front Neurosci. 2018 Nov 21;12:854. doi: 10.3389/fnins.2018.00854. eCollection 2018.

34.

Increased mean R2* in the deep gray matter of multiple sclerosis patients: Have we been measuring atrophy?

Hernández-Torres E, Wiggermann V, Machan L, Sadovnick AD, Li DKB, Traboulsee A, Hametner S, Rauscher A.

J Magn Reson Imaging. 2019 Jul;50(1):201-208. doi: 10.1002/jmri.26561. Epub 2018 Dec 4.

PMID:
30511803
35.

Diffusely Abnormal White Matter, T2 Burden of Disease, and Brain Volume in Relapsing-Remitting Multiple Sclerosis.

Vertinsky AT, Li DKB, Vavasour IM, Miropolsky V, Zhao G, Zhao Y, Riddehough A, Moore GRW, Traboulsee A, Laule C.

J Neuroimaging. 2019 Jan;29(1):151-159. doi: 10.1111/jon.12574. Epub 2018 Oct 30.

PMID:
30376195
36.

Goodpasture's Syndrome Following Alemtuzumab Therapy in Multiple Sclerosis.

Lapointe E, Moghaddam B, Barclay K, Traboulsee AL, Neufeld P.

Can J Neurol Sci. 2018 Nov;45(6):712-714. doi: 10.1017/cjn.2018.325. Epub 2018 Oct 2. No abstract available.

PMID:
30277178
37.

Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial.

Traboulsee AL, Machan L, Girard JM, Raymond J, Vosoughi R, Hardy BW, Emond F, Gariepy JL, Bone JN, Siskin G, Klass D, Isserow S, Illes J, Sadovnick AD, Li DK.

Neurology. 2018 Oct 30;91(18):e1660-e1668. doi: 10.1212/WNL.0000000000006423. Epub 2018 Sep 28.

38.

Education, and the balance between dynamic and stationary functional connectivity jointly support executive functions in relapsing-remitting multiple sclerosis.

Lin SJ, Vavasour I, Kosaka B, Li DKB, Traboulsee A, MacKay A, McKeown MJ.

Hum Brain Mapp. 2018 Dec;39(12):5039-5049. doi: 10.1002/hbm.24343. Epub 2018 Sep 21.

PMID:
30240533
39.

Nothing Ventured, Nothing Gained? Navigating Disease-Modifying Treatment in Multiple Sclerosis.

Burton JM, Traboulsee A.

Can J Neurol Sci. 2018 Sep;45(5):487-488. doi: 10.1017/cjn.2018.317. No abstract available.

PMID:
30234473
40.

Multicenter Measurements of T1 Relaxation and Diffusion Tensor Imaging: Intra and Intersite Reproducibility.

Vavasour IM, Meyers SM, Mädler B, Harris T, Fu E, Li DKB, Traboulsee A, MacKay AL, Laule C.

J Neuroimaging. 2019 Jan;29(1):42-51. doi: 10.1111/jon.12559. Epub 2018 Sep 19.

PMID:
30230638
41.
42.

Gadolinium Deposition in Deep Brain Structures: Relationship with Dose and Ionization of Linear Gadolinium-Based Contrast Agents.

Kang H, Hii M, Le M, Tam R, Riddehough A, Traboulsee A, Kolind S, Freedman MS, Li DKB.

AJNR Am J Neuroradiol. 2018 Sep;39(9):1597-1603. doi: 10.3174/ajnr.A5751. Epub 2018 Aug 23.

43.

Reflections on translation: Views of participants in a multisite Canadian CCSVI clinical trial.

Benjaminy S, Lo C, Illes J, Traboulsee A.

Neurol Clin Pract. 2018 Jun;8(3):232-239. doi: 10.1212/CPJ.0000000000000462. Review.

44.

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis.

Kowalec K, Wright GEB, Drögemöller BI, Aminkeng F, Bhavsar AP, Kingwell E, Yoshida EM, Traboulsee A, Marrie RA, Kremenchutzky M, Campbell TL, Duquette P, Chalasani N, Wadelius M, Hallberg P, Xia Z, De Jager PL, Denny JC, Davis MF, Ross CJD, Tremlett H, Carleton BC.

Nat Genet. 2018 Aug;50(8):1081-1085. doi: 10.1038/s41588-018-0168-y. Epub 2018 Jul 16.

45.

Resilience, trust, and civic engagement in the post-CCSVI era.

Benjaminy S, Schepmyer A, Illes J, Traboulsee A.

BMC Health Serv Res. 2018 May 16;18(1):366. doi: 10.1186/s12913-018-3130-x.

46.

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.

Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM; IFNB Multiple Sclerosis Study Group and the 16- and 21-Year LTF Investigators.

Mult Scler. 2019 May;25(6):837-847. doi: 10.1177/1352458518773511. Epub 2018 May 15.

PMID:
29761737
47.
48.

A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.

Vavasour IM, Tam R, Li DK, Laule C, Taylor C, Kolind SH, MacKay AL, Javed A, Traboulsee A.

Mult Scler. 2019 May;25(6):811-818. doi: 10.1177/1352458518770085. Epub 2018 Apr 17.

PMID:
29663845
49.

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G.

Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar.

50.

What Have We Learned from Perfusion MRI in Multiple Sclerosis?

Lapointe E, Li DKB, Traboulsee AL, Rauscher A.

AJNR Am J Neuroradiol. 2018 Jun;39(6):994-1000. doi: 10.3174/ajnr.A5504. Epub 2018 Jan 4. Review.

Supplemental Content

Loading ...
Support Center